Praxis Precision Medicines
PRAX
309 hedge funds and large institutions have $11.3B invested in Praxis Precision Medicines in 2026 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 122 increasing their positions, 93 reducing their positions, and 39 closing their positions.
54% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 39
31% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 93
10% more capital invested
Capital invested by funds: $10.2B → $11.3B (+$1.05B)
6.79% more ownership
Funds ownership: 114.16% → 120.95% (+6.8%)
6% more funds holding
Funds holding: 291 → 309 (+18)
22% less funds holding in top 10
Funds holding in top 10: 23 → 18 (-5)
80% less call options, than puts
Call options by funds: $56.6M | Put options by funds: $283M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$183M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$151M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$98.8M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$88.4M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$69.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$298M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$120M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$77.7M |
| 4 |
Goldman Sachs
New York
|
-$51.3M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$48.4M |
PRAX Hedge Fund Activity: Q2 2026 in Review
309 of the 8,299 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2026, worth a combined $11.3B — up 10% from $10.2B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new PRAX positions and 39 closed out — a net gain of 21 holders — while 122 added to existing stakes and 93 trimmed.
The largest buyer was Vanguard Portfolio Management, adding an estimated $183M. The largest seller was Orbis Allan Gray, cutting an estimated $298M.
- 309 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2026, up from 291 in Q1 2026.
- Funds reported $11.3B of Praxis Precision Medicines stock for Q2 2026, up 10% quarter-over-quarter.
- 60 funds opened new Praxis Precision Medicines positions in Q2 2026 and 39 closed out, a net change of +21 holders.
- The largest Praxis Precision Medicines buyer in Q2 2026 was Vanguard Portfolio Management, an estimated $183M added.
- The largest Praxis Precision Medicines seller in Q2 2026 was Orbis Allan Gray, an estimated $298M sold.
Based on aggregated 13F filings for Q2 2026.